John M. Vierling

Feb 21, 2024 | nejm.org | Christopher L. Bowlus |Andreas Kremer |John M. Vierling |Kris V. Kowdley

February 29, 2024N Engl J Med 2024; 390:783-794 DOI: 10.1056/NEJMoa2312100 AbstractEffective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits.

Oct 17, 2023 | thelancet.com | Kris V. Kowdley |John M. Vierling |Nishit B Modi |Kevork Peltekian

Summary Hereditary haemochromatosis protein (HFE)-related haemochromatosis, an inherited iron overload disorder caused by insufficient hepcidin production, results in excessive iron absorption and tissue and organ injury, and is treated with first-line therapeutic phlebotomy. We aimed to investigate the efficacy and safety of rusfertide, a peptidic mimetic of hepcidin, in patients with HFE-related haemochromatosis.